Global Transcriptomics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2031

Transcriptomics Market Analysis

The global transcriptomics market is experiencing significant growth, driven by advancements in technologies such as next-generation sequencing (NGS) and microarray analysis. The increasing prevalence of diseases and the rising demand for personalized medicine are major factors fueling this market expansion. Additionally, the advent of innovative bioinformatics tools enhances the analysis and interpretation of large transcriptomic datasets, further propelling market development. The application of transcriptomics in drug discovery and development is also expanding, as researchers leverage gene expression profiling to identify biomarkers and therapeutic targets. Overall, the transcriptomics market is poised for robust growth as it plays a crucial role in understanding gene functions and disease mechanisms, ultimately improving patient outcomes.

Transcriptomics Market Size

The global transcriptomics market size was valued at USD 7.64 billion in 2023 and is projected to reach USD 15.99 billion by 2031, with a CAGR of 9.68% during the forecast period of 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Transcriptomics Market Trends

“Rising Adoption of Single-Cell RNA Sequencing”

Рынок транскриптомики переживает значительный рост, обусловленный растущим принятием секвенирования РНК отдельных клеток, ключевой тенденции, повышающей точность исследований и понимание на клеточном уровне. Эта технология позволяет исследователям анализировать экспрессию генов в отдельных клетках, что имеет решающее значение для понимания сложных биологических процессов, особенно в таких областях, как онкология и нейробиология. Например, секвенирование РНК отдельных клеток сыграло важную роль в идентификации редких типов клеток в опухолях, что помогает в разработке целевых методов лечения рака. Основные игроки на рынке транскриптомики, такие как 10x Genomics и NanoString Technologies, все больше внимания уделяют развитию платформ отдельных клеток для удовлетворения высокого спроса на подробные масштабируемые транскриптомные данные. Эта тенденция подкрепляется партнерскими отношениями между исследовательскими институтами и лидерами отрасли, что дополнительно поддерживает рост рынка за счет расширения областей применения и улучшения разрешения данных. По мере того, как технология продолжает развиваться, ожидается, что секвенирование РНК отдельных клеток будет стимулировать как инновации, так и инвестиции на мировом рынке транскриптомики.

Область применения отчета и сегментация рынка транскриптомики     

Определение рынка транскриптомики

Транскриптомика — это изучение транскриптома, полного набора транскриптов РНК, производимых геномом при определенных обстоятельствах или в определенной клетке. Эта область фокусируется на анализе уровней и моделей РНК для понимания экспрессии и регуляции генов. Изучая транскриптом, ученые получают представление о том, как гены включаются или выключаются в различных тканях, на разных стадиях развития или в ответ на различные условия, что делает его важным в таких областях, как исследование болезней, разработка лекарств и персонализированная медицина.

Динамика рынка транскриптомики

Драйверы

• Рост распространенности хронических заболеваний

Растущая распространенность хронических заболеваний существенно влияет на рынок транскриптомики, увеличивая спрос на расширенный анализ экспрессии генов. Например, по данным Всемирной организации здравоохранения (ВОЗ), хронические заболевания, включая рак и сердечно-сосудистые заболевания, являются причиной примерно 70% всех смертей в мире, причем только от рака в 2020 году умерло около десяти миллионов человек. Эта тревожная тенденция подчеркивает актуальность исследований, направленных на понимание молекулярных механизмов, лежащих в основе этих заболеваний. В результате фармацевтические и биотехнологические компании вкладывают значительные средства в транскриптомику для обнаружения биомаркеров заболеваний и разработки инновационных методов лечения, тем самым стимулируя рост рынка транскриптомики. Такое сочетание растущей заболеваемости и потребности в передовых исследовательских инструментах делает транскриптомику важнейшим компонентом в решении проблем, связанных с хроническими заболеваниями.

• Увеличение финансирования биомедицинских исследований

Увеличение финансирования биомедицинских исследований является важным драйвером рынка транскриптомики, поскольку оно способствует разработке и внедрению передовых технологий, необходимых для анализа экспрессии генов. Например, Национальный институт здравоохранения (NIH) в США сообщил об инвестициях в биомедицинские исследования в размере более 41 миллиарда долларов США в 2022 году, что является заметным ростом по сравнению с предыдущими годами. Это финансирование поддерживает широкий спектр исследовательских инициатив, включая те, которые используют транскриптомику для изучения сложных биологических процессов, таких как механизмы заболеваний и терапевтические реакции. Приток государственного и частного финансирования способствует инновациям в технологиях транскриптомики и расширяет их применение в разработке лекарств, точной медицине и диагностике заболеваний, тем самым стимулируя общий рост рынка.

Opportunities

• Increasing Technological Advancements in Sequencing Technologies

Technological advancements in sequencing technologies, particularly next-generation sequencing (NGS) and single-cell RNA sequencing, are creating substantial opportunities in the transcriptomics market by enhancing the accuracy, speed, and cost-effectiveness of gene expression analyses. For instance, NGS has revolutionized transcriptomics by enabling high-throughput sequencing of RNA, allowing researchers to analyze thousands of genes simultaneously at a fraction of the cost and time compared to traditional methods. A notable instance is the use of single-cell RNA sequencing, which enables the examination of gene expression at the individual cell level, providing insights into cellular heterogeneity and enabling the discovery of rare cell populations that may play critical roles in diseases. As these technologies continue to evolve, they are expanding the applications of transcriptomics in drug discovery, diagnostics, and personalized medicine, thus representing a significant market opportunity for companies engaged in the development of sequencing platforms and related technologies.

• Growing Application in Drug Discovery and Development

Transcriptomics is increasingly recognized as a vital component in drug discovery and development, as it aids in identifying potential drug targets and elucidating the mechanisms of drug action. For instance, the integration of transcriptomic data has been instrumental in the development of targeted therapies, such as the use of RNA sequencing to uncover biomarkers for drug response in cancer treatments. A compelling instance is the identification of gene expression profiles that predict patient responses to therapies such as trastuzumab (Herceptin) in HER2-positive breast cancer, as highlighted in a study published in Nature Medicine. This has improved patient outcomes and streamlined clinical trial designs by allowing for more precise patient stratification. As pharmaceutical and biotechnology companies increasingly incorporate transcriptomic analyses into their research pipelines, there is a growing market opportunity for technologies that facilitate these analyses, enabling the development of more effective therapeutics and personalized medicine approaches.

Restraints/Challenges

• Affordability and Cost Barriers

High costs represent a significant challenge in the transcriptomics market, as the expenses associated with various stages of transcriptomic analysis including sample preparation, sequencing, and data analysis can be prohibitive, particularly for smaller laboratories and research institutions. For instance, the cost of high-throughput sequencing platforms can exceed hundreds of thousands of dollars, and additional expenses for reagents, maintenance, and personnel training further escalate the financial burden. Recent studies have indicated that the average cost for RNA sequencing can vary widely, depending on the depth of sequencing and the complexity of the analysis required. These high costs can severely limit the ability of smaller labs to adopt cutting-edge transcriptomic technologies, leading to a reliance on traditional methods that may not provide the same depth of information. As a result, this financial barrier restricts access to innovative research tools and stifles the advancement of the field, making it difficult for smaller institutions to compete with larger entities that have the resources to invest in these technologies. Therefore, addressing the cost issue is crucial for democratizing access to transcriptomics and fostering innovation across the scientific community.

• Complex Regulatory Frameworks

Regulatory challenges pose a significant obstacle in the transcriptomics market, particularly in clinical applications where strict guidelines govern the use of genetic information in diagnostics and therapeutics. The process of navigating the regulatory landscape can be time-consuming and complex, often requiring extensive documentation, validation studies, and compliance with regional and international regulations. For instance, when companies seek to bring transcriptomic-based diagnostics to market, they may need to demonstrate the analytical validity of their tests and their clinical utility, which can involve costly and lengthy clinical trials. A notable case is the regulatory pathway for liquid biopsy tests that utilize transcriptomic data; companies such as Grail faced substantial scrutiny from regulatory bodies such as the FDA, which necessitated comprehensive data to support claims of efficacy and safety. Delays in receiving regulatory approvals can hinder product development timelines and limit market entry, ultimately impacting innovation and the availability of advanced transcriptomic technologies to clinicians and researchers. Therefore, addressing these regulatory challenges is essential to foster a more conducive environment for the growth of the transcriptomics market and ensure timely access to its benefits in clinical settings.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Transcriptomics Market Scope

The market is segmented on the basis of product and services, technology, application, and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product and Services

• Instruments
  • Mode
    • Automated
    • Semi-automated
    • Manual
  • Type
    • Sequencing Platforms
    • IHC
    • Microscopy
    • Flow Cytometry
    • Mass Spectrometry
    • Others
• Consumables
• Software
  • Bioinformatics Tools
  • Imaging Tools
  • Storage and Management Databases
• Services

Technology

• Microarray
• Real-Time PCR (qPCR)
• Sequencing

Application

• Diagnostics and Disease Profiling
• Drug Discovery
• Others

End User

• Pharmaceutical and Biotechnology Companies
• Government Institutes and Academic Centers
• Contract Research Organizations (CROs)

Transcriptomics Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product and services, technology, application, and end user as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America holds a leading position in the transcriptomics market, largely due to strategic investments in disease pathology research that have fueled advancements in the field. The region's commitment to innovation and funding in transcriptomics R&D is expected to drive further market growth. Increasing focus on understanding disease mechanisms at the transcriptomic level has bolstered research initiatives, encouraging both public and private investment. As a result, North America is projected to see continued expansion in transcriptomics capabilities and market share during the forecast period.

Asia-Pacific is anticipated to experience strong growth, driven by increasing international collaborations and partnerships with Asian research institutions. These collaborations have enhanced the region's capabilities in transcriptomic research, leading to new applications and innovations. Additionally, initiatives focused on evaluating system performance and developing diverse uses for transcriptomics platforms are expected to boost market expansion. With these efforts, Asia-Pacific is poised for substantial growth in the transcriptomics market over the coming years.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.  

Transcriptomics Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Transcriptomics Market Leaders Operating in the Market Are:

• Agilent Technologies, Inc. (U.S.)
• Illumina, Inc. (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Beckman Coulter, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• BD (U.S.)
• Sartorius AG (Germany)
• BIOMÉRIEUX (France)
• Bio-Rad Laboratories, Inc. (U.S.)
• Cepheid (U.S.)
• Takara Bio Inc. (Japan)
• Cytognomix Inc. (Canada)
• GENERAL ELECTRIC COMPANY (U.S.)
• Siemens (Germany)
• QIAGEN (Netherlands)
• Merck KGaA (Germany)
• AffiPCR (U.S.)
• 10x Genomics (U.S.)
• Bruker Spatial Biology, Inc. (U.S.)

Latest Developments in Transcriptomics Market

• In April 2024, Lexogen, a biotech firm specializing in RNA research, introduced new solutions specifically designed for transcriptome profiling of formalin-fixed paraffin-embedded (FFPE) samples. These "biobank" samples are invaluable for researchers in fields such as cancer research, drug discovery, and development
• In March 2024, Insilico Medicine ("Insilico") launched the PandaOmics Box, a hardware platform designed for data privacy and security in biological analytics. PandaOmics Box operates without Internet access, enabling on-premise target identification, biomarker discovery, indication prioritization, and advanced research in personalized medicine and drug discovery
• In March 2024, 10x Genomics, Inc., a leader in single-cell and spatial biology, announced the commercial release of its Visium HD Spatial Gene Expression assay. This product allows researchers to measure the whole transcriptome from FFPE tissue sections at single-cell resolution
• In February 2024, NanoString Technologies, Inc., a leader in life science research tools, launched the CosMx Human 6K Discovery Panel. This single-cell spatial panel allows researchers to study over 6,000 RNA targets, covering nearly all human biological pathways. NanoString, along with independent researchers, also highlighted the product's whole transcriptome imaging capability at the Advances in Genome Biology and Technology (AGBT) General Meeting in Orlando, Florida, held from February 5-8
• In February 2023, Curio Bioscience launched commercial operations with the introduction of Curio Seeker, the world’s first high-resolution, whole-transcriptome spatial mapping kit. Based on the Slide-seq technique developed by its co-founders at the Broad Institute of MIT and Harvard, Curio Seeker enables labs to create whole-transcriptome spatial data from tissue samples through an easy-to-use workflow

SKU-46241